Education
About Us
Working with TipRanks
Follow Us
Active Biotech AB (DE:BTPC)
FRANKFURT:BTPC
BTPC Stock Chart & Stats
€0.01
<€0.01(14.29%)
At close: 4:00 PM EST
€0.01
<€0.01(14.29%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.03
Previous CloseN/A
Volume20.00K
Average Volume (3M)7.13K
Market Cap
€11.85M
Enterprise Value-€6.47M
Total Cash (Recent Filing)€65.10M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-7.12
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,636,067,100
10 Day Avg. Volume2,383
30 Day Avg. Volume7,129
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.11
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Increasing Total Assets (improved Balance-sheet Capacity)An increase in total assets to 70.2M (from 43.2M) strengthens the company's balance-sheet capacity to fund R&D, support partner collaborations, or be used in financing structures. This tangible asset growth provides durable optionality to monetize programs or secure non-dilutive financing.
Very Low / Zero Reported DebtNear-zero debt reduces fixed financial obligations and interest risk, giving management flexibility to time financings or pursue licensing deals without servicing large borrowing costs. Low leverage supports long-term survivability through clinical cycles and preserves cash for priority programs.
Out-licensing And Partnering Business ModelA licensing-focused model shifts late-stage development and commercialization costs to partners, lowering required capital intensity and operating scale. Durable benefit: successful partnerships can generate upfront, milestone, and royalty streams without building a commercial infrastructure, aligning costs with program de-risking.
Bears Say
No Revenue And Persistent Net LossesZero reported revenue across multiple years means operations cannot be sustained from internal cash generation; persistent annual losses (~-37.3M in 2025) erode equity and require continual external funding. Over the medium term this undermines financial resilience and increases dilution risk if financing is needed.
Consistent Negative Operating Cash Flow (cash Burn)Material negative operating cash flow (roughly -32.4M in 2025) demonstrates ongoing cash burn despite improvements. Continued negative cash flows create structural dependency on equity raises, partner milestone timing, or asset sales, constraining strategic choices and potentially forcing dilutive financings during critical development windows.
No Marketed Products; Revenue Tied To Partner MilestonesReliance on milestone and royalty payments rather than product sales makes revenue timing binary and unpredictable. Structural risk: partners control development progress and payment triggers, limiting Active Biotech's cash visibility and making business sustainability highly contingent on external program advances and deal execution.
Active Biotech AB News
BTPC FAQ
What was Active Biotech AB’s price range in the past 12 months?
Active Biotech AB lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.
What is Active Biotech AB’s market cap?
Active Biotech AB’s market cap is €11.85M.
When is Active Biotech AB’s upcoming earnings report date?
Active Biotech AB’s upcoming earnings report date is May 07, 2026 which is in 62 days.
How were Active Biotech AB’s earnings last quarter?
Active Biotech AB released its earnings results on Feb 12, 2026. The company reported >-€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by >-€0.001.
Is Active Biotech AB overvalued?
According to Wall Street analysts Active Biotech AB’s price is currently Overvalued.
Does Active Biotech AB pay dividends?
Active Biotech AB does not currently pay dividends.
What is Active Biotech AB’s EPS estimate?
Active Biotech AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Active Biotech AB have?
Active Biotech AB has 2,636,067,100 shares outstanding.
What happened to Active Biotech AB’s price movement after its last earnings report?
Active Biotech AB reported an EPS of >-€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Active Biotech AB?
Currently, no hedge funds are holding shares in DE:BTPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Active Biotech AB
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
Technical Analysis
Medivir AB
―
Isofol Medical AB
―
Xintela AB
―
Elicera Therapeutics AB
―
IRLAB Therapeutics AB Class A
―